|
Posted: 2:40 PM Feb 8, 2012
FDA panel votes against Xgeva for prostate cancer
Washington A panel of cancer experts has voted against a new use for Amgen's Xgeva in prostate cancer, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients.
Reporter: The Associated Press Email Address: katherine.rufener@wndu.com |
|
0 Comments 
A panel of cancer experts has voted against a new use for Amgen's Xgeva in prostate cancer, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients.
The Food and Drug Administration's cancer drug panel voted 12-1 that the benefits of the drug did not outweigh its risks, which included bone disease in about 6 percent of patients. The FDA is not required to follow the group's advice, though it often does.
Xgeva is already approved for preventing fractures in cancerous bones, and for osteoporosis, in a different formulation called Prolia.
Amgen has asked the FDA to approve the injectable drug as a preventive measure for men with recurring prostate cancer that is at high risk of spreading to the bone.
| WNDU News Poll |
| There are currently no active polls at this time. Click here to view other polls on our site and past poll results. |
- Small dairies go under as milk prices sink again
- Public nudity in San francisco is legal
- Senator: Prostitution scandal wider than believed
- Passenger's suspicious claim diverts jet to Maine
- US Army more selective on recruits, re-enlistments
- States turning to new tolls to pay for highways
- Man survives 180-foot plunge over Niagara Falls
- More support needed for kinship caregivers
- Private rocket blasts off for space station
- TransUnion: Late auto-loan payments down in 1Q
